Link between physician training brand name prescribing found
Physicians in training are twice as likely to order a costly brandname statin used to lower blood cholesterol levels when supervised by senior physicians who prefer those medications in their own...
View ArticleStudy finds link between physician training and brand name prescribing
Physicians in training are twice as likely to order a costly brandname statin used to lower blood cholesterol levels when supervised by senior physicians who prefer those medications in their own...
View ArticleEuropean Commission Approves Amgen's New CholesterolLowering Medication...
THOUSAND OAKS Calif. July 21 2015 PRNewswire &160;Amgen NASDAQAMGN today announced that the European Commission EC has granted marketing authorization for Repatha&8482; evolocumab the first...
View ArticleRegeneron and Sanofi Announce CHMP Recommends European Approval of PraluentÂ...
TARRYTOWN N.Y. and PARIS July 24 2015 PRNewswire &160;Regeneron Pharmaceuticals Inc. NASDAQ REGN and Sanofi today announced that the European Medicine Agency's EMA's Committee for Medicinal...
View ArticleDr. Nathan D. Wong to Deliver Opening Lecture at International Academy of...
Asher Kimchi M.D. Founder and Chairman of the International Academy of Cardiology today announced the selection of Nathan D. Wong Ph.D. MPH Professor and Director Heart Disease Prevention Program...
View ArticleHow Many Americans Could be Treated with new PCSK9 Inhibitors Hint It Won't...
WASHINGTON July 24 2015 PRNewswireUSNewswire Despite claims that tens of millions of Americans could be eligible for treatment with a new class of cholesterollowering medications called PCSK9...
View ArticleSanofi and Regeneron Announce CHMP Recommends European Approval of PraluentÂ...
Sanofi and Regeneron Announce CHMP Recommends European Approval of Praluent alirocumab for the Treatment of Hypercholesterolemia Paris and Tarrytown New York July 24 2015 Sanofi and Regeneron...
View ArticleRegeneron and Sanofi Announce FDA Approval of Praluent alirocumab Injection...
TARRYTOWN N.Y. and PARIS July 24 2015 PRNewswire &160;Regeneron Pharmaceuticals Inc. NASDAQ REGN and Sanofi today announced that the U.S. Food and Drug Administration FDA approved Praluent&174;...
View ArticleSanofi and Regeneron Announce FDA Approval of Praluent alirocumab Injection...
PARIS and TARRYTOWN N.Y. July 24 2015 PRNewswire &160;Sanofi and Regeneron Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration FDA approved Praluent&174; alirocumab...
View ArticleRevised Draft v2.0 Esperion ESPR Dives 20 in Response to Lackluster Label for...
On Thursday July 24 Praluent a PCSK9 inhibitor from Regeneron Sanofi was approved by the FDA. This was no surprise. We expected this drug to receive approval.It was approved for use in addition to diet...
View ArticleEsperion ESPR Dives 20 in Response to Lackluster Label for PCSK9 Drug Approval
On Thursday July 24 Praluent a PCSK9 inhibitor from Regeneron Sanofi was approved by the FDA. This was no surprise. We expected this drug to receive approval.It was approved for use in addition to diet...
View ArticleSanofi and Regeneron Announce FDA Approval of Praluent alirocumab Injection...
Sanofi and Regeneron Announce FDA Approval of Praluent alirocumab Injection the First PCSK9 Inhibitor in the U.S. for the Treatment of High LDL Cholesterol in Adult Patients Praluent available early...
View ArticleFDA approves Praluent
FDA approved a BLA on Friday for PCSK9 inhibitor Praluent alirocumab from Regeneron Pharmaceuticals Inc. NASDAQREGN and Sanofi EuronextSAN; NYSESNY. The human mAb against PCSK9 is the first approved in...
View ArticleEsperion ESPR Dives 20 in Response to "Lackluster Label" for Praluent's...
On Friday July 24 2015 Praluent a PCSK9 inhibitor from Regeneron Sanofi was approved by the FDA. This was no surprise.It was approved for use in addition to diet and maximally tolerated statin therapy...
View ArticleEsperion ESPR Dives 20 in Response to "Lackluster Label" for PCSK9 Drug Approval
On Thursday July 24 2015 Praluent a PCSK9 inhibitor from Regeneron Sanofi was approved by the FDA. This was no surprise.It was approved for use in addition to diet and maximally tolerated statin...
View ArticleNervous Times and Acquisition Windows for Esperion ESPR
We review the upcoming major events in the next 9 months that could push down ESPR. We normally take a much longer time frame but we recently finished a major post concerning the impact of Praluents...
View ArticleCholesterol Drugs New Studies Could Spur Even Wider Use. Is That a Good Thing
By STEVEN FINDLAY Chances are that a third of you reading this sentence take a statin the ubiquitous cholesterollowering drugs. I do. Is it a good or bad thing that so many of us are taking these meds...
View ArticleMore people should be taking statins for primary prevention US study suggests
US guidelines that set the threshold for starting statin therapy at a lower level than the threshold recommended by the National Institute for Health and Care Excellence in England are cost effective...
View ArticleFDA approves Sanofi Regenerons Praluent alirocumab Injection
The FDAÂhas approved SanofiÂand Regeneron Pharmaceuticals PraluentÂalirocumab Injection the first FDAapproved treatment in a new class of drugs known as PCSK9 proprotein convertase subtilisinkexin type...
View ArticleTopline Results for Esperion's ESPR ETC1002 in Hypertensive Patients Study 014
On Tuesday July 28 2015 Esperion Therapeutics ESPR reported a 21 reduction p < 0.0001 from baseline and a 24 reduction versus the placebo group.
View Article